A method for treating ulcerative colitis using combination therapy with antibodies against IL-23 and TNF-alpha.

Combining IL-23 and TNF-α inhibitors addresses the limitations of monotherapies in ulcerative colitis by enhancing remission rates and safety, offering a more effective treatment paradigm.

JP2026517801APending Publication Date: 2026-06-02JANSSEN BIOTECH INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
JANSSEN BIOTECH INC
Filing Date
2024-05-02
Publication Date
2026-06-02

Smart Images

  • Figure 2026517801000001
    Figure 2026517801000001
  • Figure 2026517801000002
    Figure 2026517801000002
  • Figure 2026517801000003
    Figure 2026517801000003
Patent Text Reader

Abstract

A method for treating ulcerative colitis (UC), comprising administering a combination of an IL-23 inhibitor such as an anti-IL-23p19 antibody (e.g., guselkumab) and a TNF-α inhibitor such as an anti-TNF-α antibody (e.g., golimumab).
Need to check novelty before this filing date? Find Prior Art